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Abstract
Purpose of Review To describe lipid abnormalities in diabetes, when they occur and the evidence base for lipid management with
established and new drugs to prevent diabetes complications. We also discuss how to manage statin intolerance.
Recent Findings Statins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have
emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and
effective in diabetes. Emerging evidence suggests a need to consider lipid-lowering therapies more often in younger patients with
both type 1 and type 2 diabetes.
Summary Statins remain the cornerstone of lipid management in diabetes but other options are increasing. There is also now
evidence for better managing apparent statin intolerance. Notably, younger patients lose the most life years from their diabetes, an
observation that future guidelines need to consider.
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Introduction
Diabetes is a well-recognized risk factor for cardiovascular
disease (CVD) and while hyperglycemia enhances risk, such
patients are often obese, have hypertension, and are character-
ized by a specific dyslipidemia, such that the CVD risk in
diabetes is multifactorial. Notably, one could say that nearly
all patients with type 2 diabetes (T2DM) have lipid abnormal-
ities. However, only in the late 1990s to 2000s, after major
statin trials and relevant guideline changes, did we start to
aggressively treat these lipid abnormalities, at least in high-
income countries. For the next two decades or so, statins
formed the cornerstone of lipid-lowering therapy in diabetes.
This statin-dominated pattern has not changed, but additional
ways to lessen LDL-C have emerged, and thus doctors have
more therapies in their armory to treat dyslipidemia (Table 1).
Furthermore, there is a push for some particularly high-risk
patients to be treated more aggressively. There is also discus-
sion surrounding when and how to treat younger patients with
T2DMwho have particularly elevated risk for CVD and great-
er premature mortality. Finally, although we focus mostly on
lipids in T2DM, emerging data suggest we may be
undertreating lipid levels in people with type 1 diabetes
(T1DM), who lose on average more life years than those with
T2DM. These aspects are discussed in more detail in this short
review of the field.
What Are the Lipid Abnormalities in T2DM?
Dyslipidemia is an important biochemical abnormality in pa-
tients with T2DM, because of its independent association with
an increased risk of morbidity and mortality from CVD [1–3].
Characteristically, these lipid abnormalities are high fasting
and postprandial plasma triglyceride (TG) concentration,
low levels of high density lipoprotein cholesterol (HDL-C),
and normal or slightly increased concentration of low-density
lipoprotein cholesterol (LDL-C), and increased numbers of
small dense LDL (sdLDL) particles. Apolipoprotein B
(ApoB), a carrier protein in both LDL and VLDL, is also
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raised. Increased mobilization of free fatty acids (FFA) from
adipose tissue, in addition to impaired insulin-mediated skel-
etal muscle uptake, results in increased circulating FFA levels,
increased hepatic fatty acid influx, and TG formation [4, 5].
Traditionally, LDL size and density are linked with CVD
[6, 7], as well as LDL particle concentration, with small dense
LDL particles postulated as having the greatest contribution to
atherogenic disease. The etiology of this has shown to be
multifactorial with in vitro studies demonstrating reductions
in LDL receptor affinity [8], increased arterial wall binding of
LDL [9], and altered LDL oxidation [10], each contributing to
increased CVD risk. Reduced HDL concentration is usually
characterized by reduced levels of subspecies HDL2 and is
often associated with high TG levels [11]. Patients with
T2DM are also likely to have smaller HDL particles.
However, another way to view lipid-associated risk in
T2DM stems from genetic evidence from Ference et al. In
their recent work, they compared the association of
triglyceride-lowering LPL variants and LDL-C–lowering
LDLR variants with the risk of CVD per unit difference in
Apo B, to demonstrate that reducing both TG and LDL-C
variants was associated with lower CHD risk per unit lower
level of Apo B-containing lipoproteins [12]. Thus, it appears
that the number of ApoB containing particles is the most
important predictor of CVD risk, and therefore in patients with
T2DMwith raised TG levels, ApoB tends to be higher (due to
accumulation of VLDL particles and smaller dense LDL)
resulting in a raised lipid-associated risk for CVD. Whether
apo B should be recommended for risk assessment in people
with diabetes is a topical issue. It is our view that routine
measurement of apo B is not presently needed given that a
diagnosis of diabetes itself warrants lipid lowering and that
non-HDL-cholesterol, which is high in diabetes, is available
as a secondary lipid target. In recent analyses of UK biobank
data, we showed that once total cholesterol and HDL-
cholesterol were factored into a cardiovascular risk score,
apo B adds little further predictive value [13]. We recognise
some researchers remain strongly in favour of measuring apo
B buts its far greater cost and limited added prediction benefit,
means its addition is unlikely to be cost effective.
When Evidence Base for Statin Use in Diabetes
Became Unquestionable
Throughout the 1990s and 2000s, a body of evidence demon-
strating the benefits of statin therapy, both in the general pop-
ulation and in patients with diabetes, was created. The trials
conducted had differing recruitment criteria, different
Table 1 Summary of trial evidence for lipid lowering in type 2 diabetes
Classification of drug Key trials Findings Clinical implications
Statins CTT LDL-C reduction of 1 mmol/L results in approximately
23% reduction in CVevent.
Intensive statin regimes result in statistically significant
15% further reduction in major vascular events,
without significant side effects.
Statins as first line in patients with diabetes.
Nowadays, the most commonly used are
atorvastatin and rosuvastatin. Both have
greater benefits on TG reduction than the
older simvastatin and pravastatin.
Ezetimibe IMPROVE-IT Reduced CV mortality, major CVevent and stroke by
5.5% absolute RR (hazard ratio, 0.85; 95% confidence
interval, 0.78–0.94)
The largest relative reductions occurred in patients with
DM were in MI (24%) and stroke (39%).
First add-on therapy if patients are not reaching
targets for LDL-c or non-HDL-c despite
maximally tolerated statin therapy
PCSK9 inhibitor FOURIER Evolocumab reduced cardiovascular outcomes in
patients with diabetes: HR 0.83 (95% CI 0.75–0.93;
p = 0.0008) for primary composite endpoint. Similar
data for Alirocumab.
Currently reserved for patients at very high
absolute risk for CVD. This includes patients
with FH or existing CVD, with sustained
elevations in LDL-c despite maximally toler-
ated statin therapy plus ezetimibe.
Fibrates ACCORD Modest changes seen in the reduction of TG levels and
increase in HDL-C levels.
Add-on to statins for mixed hyperlipidemia,
without robust evidence demonstrating
improved outcomes in CVD risk. Further
ongoing trials with newer fibrates.
Icosapent ethyl;
Eicosapentaenoic
acid (EPA) ethyl
ester
REDUCE-IT Primary endpoint event occurred in 17.2% of treated
patients compared with 22.0% in placebo group (HR
0.75; 95% CI 0.68 to 0.83; p < 0.001)
Potential new therapy with modest lowering of
TG levels. Outcome benefits may be largely
independent of TG lowering. Ongoing trials
of similar agents should help reveal
mechanisms in due course.
Bempedoic acid;
ATP citrate lyase
inhibitor
CLEAR-Harmony Treatment reduced the mean LDL cholesterol level
− 16.5% from baseline (difference vs. placebo in
change from baseline, − 18.1 percentage points; 95%
CI, − 20.0 to − 16.1; p < 0.001).
Potential new therapy for LDL cholesterol
lowering
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outcomes with varying analyses and different drugs were stud-
ied. In 2005, the Cholesterol Treatment Trialists’ (CTT)
Collaboration published a prospective meta-analysis utilizing
data from 14 randomized trials of statin therapy, including
data from 90,056 individuals [14]. With the increased power
from the combined data, they showed that statin therapy sta-
tistically reducedLDL-C, and thereforeCVD risk, over 5 years
in an approximately linear fashion. Overall, LDL-C was ap-
proximately 0.8 mmol/L lower at 5 years in patients treated
with statins. CTT demonstrated that a reduction of LDL-C of
1 mmol/L at 5 years result in an approximately 23% reduction
in CV event, and that ultimately, the absolute benefit to be
gained is based upon the individual’s baseline risk.
Therefore, patients with T2DM stand to benefit more than
those without diabetes from statin therapy. In 2010, the CTT
collaboration furthered their analyses to assess the benefits of
intensive LDL cholesterol lowering with statin therapy [15].
They looked at studies with an intensive versus standard re-
gime (five studies) and those with a statin versus control re-
gimes (21 studies). Intensive regimes resulted in a statistically
significant 15% further reduction in major vascular events
(p < 0.0001) compared with standard regimes, and the mean
further reduction in LDL-C at 1 year was 0.51 mmol/L.
Across all patients studied, further reductions in LDL-C re-
sulted in the reduction of incident CVevents by approximately
one fifth for each 1.0 mmol/L reduction. These findings oc-
curred without an increase in side effects, and the CTTcollab-
oration has subsequently published a statement highlighting
statin safety and tolerability [16].
For these reasons, statins are considered first-line treat-
ments for many with T2DM, even at diagnosis, and in those
patients with multiple risk factors for CVD, high-dose statin is
recommended (Table 1).
Other Proven Cardioprotective Cholesterol-Lowering
Therapies in Diabetes
Ezetimibe
Ezetimibe selectively inhibits dietary and biliary cholesterol
resulting in a reduction in LDL-C, a very modest increase in
HDL-C (1–3%), and has no effect on TG. Prior to 2015, the
evidence base for CVrisk reduction with ezetimibe was equiv-
ocal [17–19], with the ENHANCE-trial failing to show im-
proved CV outcomes [20]. However, in 2015, the Improved
Reduction of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT) which randomized 18,144 patients with ACS
to simvastatin 40 mg plus ezetimibe 10 mg daily or simvastat-
in alone [21] was the first trial to demonstrate improved CV
outcomes using a statin plus a non-statin add-on. Simvastatin
plus ezetimibe reduced the primary outcome of CV mortality,
major CVevent, or stroke by 34.7 vs. 32.7%; (p = 0.016) and
demonstrated a reduction inMI and stroke. These results were
likely due to LDL-C lowering, and this resulted in a change to
guidelines to include ezetimibe therapy as an add-on to statin
therapy. Furthermore, in 2018, a subgroup analysis of the 27%
of patients in IMPROVE-IT with baseline diabetes suggested
that the effect of ezetimibe was in fact most beneficial in
patients with diabetes [22••], as demonstrated in Fig. 1.
Indeed, if we take this figure at face value, it appears that the
relative risk (RR) reduction from ezetimibe was evident only
in those with T2DM. One suspects this is somewhat of a
chance finding, but nevertheless, the striking findings in those
with diabetes will lead to greater consideration of ezetimibe in
diabetes when patients are either unable to tolerate a statin or
when they are far from target values despite maximally toler-
ated statin dose.
PCSK9 Inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors are a modern class of monoclonal antibody injectable ther-
apies developed to lower LDL-C by reducing the degradation
of LDL receptors in the liver and increasing LDL-C clearance.
Currently in the UK and other high-income countries,
evolocumab and alirocumab are available for patients with fa-
milial hypercholesterolaemia with persistently raised LDL-C,
or very high-risk patients, and are given as injections either
two- or four-weekly. Recent trial evidence clearly demonstrates
their clinical efficacy. The FOURIER trial, a large randomized,
double-blind, placebo-controlled trial conducted on high-risk
patients demonstrated that evolocumab, in addition to statin
therapy, lowered baseline LDL-C by 59% compared with pla-
cebo, with a corresponding reduction in CV risk (hazard ratio
(HR), 0.85; 95% confidence interval [CI], 0.79 to 0.92;
p < 0.001) [23]. The investigators have subsequently published
their pre-specified analysis on the 16,533 patients with diabetes
at baseline (40% of patients recruited in the FOURIER trial)
demonstrating that evolocumab was beneficial in patients with
diabetes and without, with similar levels of CV risk reduction;
primary composite endpoint without diabetes HR 0.87 (95%CI
0.79–0.96; p = 0.0052) and with diabetes HR 0.83 (95% CI
0.75–0.93; p = 0.0008) (pinteraction = 0.60) [24•]. Pertinently,
they also demonstrated that PCSK9 inhibition did not increase
the risk of diabetes or worsen glycemic control. Similarly, the
ODYSSEY trial looked at outcomes of alirocumab in addition
to statin therapy in patients following an acute coronary syn-
drome (ACS). The authors reported occurrence of a primary
end point event in 11.1% of placebo patients versus 9.5% of
alirocumab-treated patients (HR 0.86 [95% CI 0.78–0.93],
p < 0.001) [25]. They also conducted a pre-specified analysis
on patients with diabetes, showing that the drug did not in-
crease new-onset diabetes risk, and that a similar relative risk
reduction was seen in diabetes patients; HR 0.84, (95% CI
0.74–0.97) [26].
Curr Cardiol Rep (2019) 21: 147 Page 3 of 8 147
To assess the efficacy on metabolic profiling of PCSK9
inhibitors compared with statins, a large, multi-centre collab-
oration utilized circulating metabolic measures in eight popu-
lation cohorts (N = 72,185), using PCSK9 rs11591147 as an
unconfounded proxy to mimic the therapeutic effects of
PCSK9 inhibitors. In this, we concluded that genetic inhibi-
tion of PCSK9 had similar metabolic effects to statin therapy
on detailed lipid and metabolite profiles. However, PCSK9
inhibition was predicted to have weaker effects on the lower-
ing of VLDL lipids compared with statins for an equivalent
lowering of low-density lipoprotein cholesterol, potentially
translating into slightly smaller reductions in CVD risk [27].
Of course, such a small difference is unlikely to be pertinent in
very high-risk patients recommended for PCSK9 inhibitors in
clinical practice, most of whom will have LDL-c levels well
above targets.
The Evidence Base for Fibrates in Type 2 Diabetes
Peroxisome proliferator-activated receptor-α (PPAR-α) ago-
nists, or fibrates, are a class of drug used to lower TG levels
and have a modest effect on raising HDL-C levels. They are
generally considered add-on therapy to statins, but can be uti-
lized alone, and although they are less effective at lowering
total cholesterol, they can increase HDL-cholesterol and reduce
TG levels more effectively than statins. The evidence base for
use in diabetes is however limited in comparison to the strong
and consistent statin evidence. The Helsinki Heart Study
reported a significant reduction in CVD outcomes with
gemfibrozil in men with dyslipidemia [28], but neither
the Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study nor the ACCORD study showed
a reduction in total CVD outcomes in studies looking
specifically in patients with T2DM. The FIELD study
did not demonstrate a difference in the primary composite
endpoint of CHD death (p = 0.16), but it did show a re-
duction in nonfatal myocardial infarctions and revascular-
izations. It should be noted that a larger proportion of the
placebo group was commenced on statin therapy, which
may have attenuated the treatment benefit [29] in the
fenofibrate group. Five years after FIELD, the ACCORD
study group also failed to demonstrate a reduction in the
rate of fatal CV events, nonfatal myocardial infarction, or
nonfatal stroke when fenofibrate was added to simvastatin
[30], with only a modest reduction of TG levels and an
increase in HDL-C levels seen. Consequently, the use of
these drugs is generally reserved as an add-on to statins
for mixed hyperlipidemia.
There is continuing interest, however, in these drugs. Jun
and colleagues suggested that although trial findings of the
effects of fibrates were inconsistent, across the board, fibrates
did demonstrate an approximately 10% RR reduction from
major cardiovascular events and 13% RR reduction for coro-
nary events. Therefore, this class of drug may play a role in
high-risk individuals [31]; the PROMINENT study is current-
ly investigating CVoutcomes in patients with diabetes taking
Fig. 1 Ezetimibe composite
efficacy outcomes by treatments
and diabetes status. (With
permission from: Giugliano RP,
et al. Circulation 2018;137:1571–
1582) [22••]
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pemafibrate, a selective peroxisome proliferator activator
modulator-α (SPPARM-α), which in pre-trial data was shown
to reduce TG ~ 50%, increase HDL-C by 13–16% and in-
crease LDL-C by up to 13% (0.4 g daily dose) [32]. The drug
has a different structure from traditional PPAR-α agonists, but
the rationale for the study remains: that lowering TG and
inflammation will improve CVoutcomes in high-risk patients
[33]. Patients with T2DM (of longer than 12 weeks duration)
with mild-to-moderate hypertriglyceridemia (TG 2.26–
5.64 mmol/l) and low HDL-C levels (<=1.03 mmol/l), who
are either receiving moderate-to-high-intensity statin therapy,
have LDL-C ≤ 1.81 mmol/L or who are statin intolerant and
have LDL-C ≥ 2.59 mmol/L, have been randomized to either
pemafibrate therapy (0.2 mg twice daily) or placebo, with an
intention to follow up over 3.75 years.
Newer Agents Being Tested (See Also Table 1)
Over recent years, there has been a marked increase in effec-
tive drug therapies for dyslipidemia. Further to the progress
that has already been made, new agents continue to be trialed
for safety and efficacy. The REDUCE-IT trial published ear-
lier this year demonstrated a primary endpoint event occurring
in 17.2% of patients treated with 2 g of icosapent ethyl (an
eicosapentaenoic acid (EPA) ethyl ester used to lower TG
levels), compared with 22.0% of a placebo group (HR 0.75;
95%CI 0.68 to 0.83; p < 0.001). However, more patients were
hospitalized for atrial fibrillation and had significant bleeding
events in the treatment group than in the placebo group, al-
though none were fatal [34]. Also, the actual effect on TG was
extremely modest, such that many feel this drug is not work-
ing via lipid lowering per se but potentially via other
mechanisms.
Similarly for LDL-C lowering, the CLEAR-Harmony
trial published in March demonstrated significant LDL-C
reduction with bempedoic acid, an ATP citrate lyase in-
hibitor, at 12 weeks. Treatment reduced the mean LDL
cholesterol level − 16.5% from baseline (difference vs.
placebo in change from baseline, − 18.1 percentage
points; 95% CI, − 20.0 to − 16.1; p < 0.001). The safety
profile was also favorable [35]. This reduction in choles-
terol is modest, and it is likely that this agent will be
combined with other drugs so that an era of dual or com-
bined lipid-lowering drugs will soon be common place.
What the Guidelines Recommend on When to Start
Lipid Lowering and the Remaining Uncertainties
Following the 2004 CARDS study, such was the strength of
evidence reducing CVD risk with the use of statins that there
was an opinion that people with T2DM should be screened to
be excluded from statin therapy. Most guidelines use a goal-
centered approach, aiming to lower LDL-C as the primary
target of dyslipidemia in T2DM. The recommended goal is
usually to titrate LDL-C to < 1.8 mmol/L in secondary pre-
vention, with consideration given to total CV risk. That noted,
recent ESC diabetes and prediabetes, as well as dyslipidemia
guidelines, have suggested even lower targets in those with
diabetes and very high CVD risk to an LDL-C below
1.4 mmol/l [36, 37]. Total cholesterol should be titrated to <
4 mmol/L, and a TG level of < 1.5 mmol/L. In most countries,
those with T2DM aged > 40 years are recommended for
statins, regardless of baseline cholesterol. Intensive lipid-
lowering therapy with atorvastatin 80 mg is recommended
for patients with diabetes and CVD. Only in England and
Wales have doctors been told to revert to risk scoring before
statins are recommended in T2DM. The NICE guidelines sug-
gest offering atorvastatin 20 mg for the primary prevention of
CVD to people with T2DM who have a 10% or greater 10-
year risk of developing CVD, assessed using QRISK2.
Whether such risk scoring leads less people with diabetes to
receive statins will be interesting to examine.
Recently, the USA moved away from a targeted approach,
with the ACC/AHA guidelines published in Nov 2013
recommending that in patients with T2DM [38], therapy
should either be high-intensity statin therapy if the patient with
diabetes is considered high risk, or moderate-intensity therapy
if low risk. This approach is broadly similar to ESC/EAS
guidelines published in 2016 although they use targets to dif-
ferentiate treatment intensities for patients with diabetes at
differing risks for CVD. For example, those at high risk,
LDL-C target < 2.6 mmol/L (< 100 mg/dL) or a reduction of
at least 50% if the baseline is recommended, whereas for those
considered at very high risk, an LDL-C target of < 1.8 mmol/L
is suggested [38], although as noted above, targets have
lowered further in the recent ESC lipid guidelines. In general,
therefore, nearly all patients with T2DM should be on statins
at some point in their lives. Notably, those who develop
T2DM when younger [39•] have even greater excess CVD
events and mortality and so absolute health gains from statins
are likely greater. By contrast, those who develop diabetes in
their 80s lose virtually no life years if compared to those with-
out diabetes at the same age [39•].
Type 1 Diabetes: Are We Undertreating with Statins?
It is curious to note that on average, people who develop
T1DM lose around 12 years of life expectancy, whereas those
who develop T2DM lose on average around 6 years. This
might surprise many, given that people with T2DM are often
more obese and have more lipid abnormalities than those with
T1DM. However, the much earlier development of T1DM
and the longer exposure to hyperglycemia per se is of para-
mount importance to future CV risk, and as such, people with
T1DM experience on average 30 years more of hyperglyce-
mia exposure. The pattern of disease risk is also worth
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examining, with potentially more atherosclerotic disease in
T1DM driven by hyperglycemia and ensuing early renal dam-
age versus what we now believe to be a combination of excess
atherosclerosis and hemodynamically driven cardiorenal dis-
ease in T2DM, the latter drivenmore in part by the obesity and
associated metabolic perturbances. Yet, clinical experience
shows far less statin is prescribed to those with T1DM. We
have also shown that those who develop T1DM when youn-
ger have the greatest excess risks for CVD [40]. Consequently,
rather than waiting until a patient with T1DM develops evi-
dence of renal disease before commencing statins, it may be
prudent to consider statins for most with T1DM above the age
of say 30 years rather than the 40-year age threshold in T2DM.
This may be a controversial suggestion, but there is plentiful
evidence statins are safe in such age groups and that they
lower cholesterol well [41]. There is also less to fear from
statin use in women than imagined since there is no clinical
evidence of teratogenicity, although good practice would be
cessation of statin in those women aiming for pregnancy.
Statin Side Effects: Retry Statin Then Aim for Lower
Doses or Alternative Statins
Statins are, sadly, much maligned in the media for causing
considerable harm, in particular muscle aches. However, the
trial experience is vastly different with a number needed to
harm of 1 in 2000 to develop actual myositis [42].
Observational data show us that in fact well over two-thirds
of people with apparent side effects are able to take the same
dose of statin when repeated without side effects. If side ef-
fects do return, then lower dose of the same statin often works.
There is also evidence for lower side effect rates with prava-
statin or low dose rosuvastatin, and these should be considered
for patients complaining of side effects on lower dose atorva-
statin or simvastatin. Doses as low as rosuvastatin 2.5 mg
twice a week can be given to lend confidence to patients
worried about statin side effects. The dose can then be titrated
up in step wise fashion in the vast majority who tolerate this
regimen. The point being that there is no reason for the vast
majority of patients, whether or not they have diabetes, who
require statins not to be on them. A specific statement on statin
intolerance in line with these comments was published in
2015 [43].
Metabolic Control and Lipid Levels
In theclinical setting, there is someevidence that raisedTGlevels
are associated with poor glycemic control. A large, Chinese-
based study published last year showed that in 20,108 patients
being treatedwith insulin forT2DM,elevatedTGswere strongly
associatedwith inadequateglycemiccontrol;adjustedORs(95%
CIs) of having anHbA1c ≥ 53mmol/molwere 1.06 (0.98, 1.15),
1.35 (1.23, 1.48), and 3.12 (2.76, 3.53) for those with
triglyceride levels in ranges of 1.70 to 2.29, 2.30, to 3.39, and ≥
3.40 mmol/L, respectively, compared with those with triglycer-
ide levels of < 1.70mmol/L [44]. Thus, if TG levels are substan-
tiallyelevated inpatientswithT2DMdespite lipid-lowering ther-
apy, improvements in glycaemic control, if abnormal, will help
improve lipid levels.
Conclusion
Diabetes is a major CVD risk factor, with plentiful evidence
for the benefits of multifactorial risk targeting (see Table 2 for
summary points). Statins lower both cholesterol and to a lesser
extent TG levels, and they remain the cornerstone for CVD
risk reduction in diabetes. The vast majority of patients with
T2DM should be offered statin therapy at some point in their
lives, except perhaps those who develop the disease when
very old. At the very least, most should be on amoderate statin
dose, with those at highest risk or with established disease
given intensive statins and aiming for lower target LDL-C or
Non-HDL-C levels. Ezetimibe has emerged as an excellent
add-on option when targets are not reached with maximally
tolerated statin dose or in the very small minority of cases
Table 2 Summary points on lipid patterns and management in patients
with diabetes
• Diabetes patients have a more atherogenic lipid profile which
contributes to their excess risk for CVD—this is especially the case in
younger onset type 2 diabetes who tend to be more obese at diagnosis
and have higher triglyceride and lower HDL-c levels and therefore
higher non-HDL-c.
• Statins are first-line treatments in diabetes with the vast majority
benefiting from statins, and the majority of countries recommend
statins in diabetes without the need for a risk score.
•As in the general population, if side effects occur with statins in patients
with diabetes, they should be advised to retry the same statin at the
same dose since most will be fine on retrial. If not, the dose can be
lowered or alternative statin tried. Patients should be advised that the
vast majority can take some form of statin without issues and trial and
error will achieve the right statin for them.
• Ezetimibe is an excellent add-on choice for patients with diabetes when
they are not at target despite maximally tolerated statin dose or whether
they are truly intolerant.
• PCSK9 inhibitors work just as well in diabetes as in those without
diabetes and with no evidence of glycemia dysregulation. They should
be reserved for patients with diabetes are exceptionally high risk of
CVD and elevated LDL-c levels despite maximally tolerated statin
plus ezetimibe.
• If patients with diabetes continue to demonstrate higher triglyceride
levels despite statin therapy, then first consider secondary causes such
as significant hyperglycemia or obesity. Fibrates can be considered in
such patients to lower pancreatitis risk but notably, whether currently
available fibrates lower CVD risk remains an open question.
• Finally, as younger patients with both type 2 and type 1 diabetes lose the
most years of life expectancy from their diabetes, more such patients
should be offered statins earlier in the course of their lives. Future
guidelines need to consider newer evidence with respect to age of
diabetes onset and lifetime risks.
Curr Cardiol Rep (2019) 21: 147147 Page 6 of 8
when no statin is tolerated at any dose. For those at exception-
ally high risk and continuing high LDL-c levels despite statins
and ezetimibe, PCSK9 inhibitors are now available and help
lower risk. The evidence base for triglyceride-lowering agents
remains incomplete, but ongoing trials should help improve
evidence base. If patients with diabetes on statins have con-
tinuing high triglyceride levels well above 5–10 mmol/l, then
fibrates may help. However poor glycemic control should first
be considered as a contributor and improved if possible.
Finally, younger people with T2DM and more people with
T1DM than is currently the case would benefit from statins
given recent evidence showing far greater risk and loss of life
years. Such patients have greatest excess risks for adverse
CVD outcomes and experience greater life years lost.
Therefore, they have the most to gain from such therapies.
Future guidelines should consider this newer evidence.
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